Abstract
We previously reported isolating vancomycin (VAN) highly resistant Staphylococcus aureus (VRSA) strains from clinical methicillin-resistant S. aureus strains by repeating steps of in vitro mutagenesis and VAN selection. Here we describe that the in vitro susceptibility of these VRSA strains to VAN was markedly increased by combined treatment with β-lactams such as ceftriaxone and oxacillin. Furthermore, in an in vivo silkworm infection model with VRSA, a combination of VAN and ceftriaxone exhibited therapeutic effects, whereas a combination of VAN and oxacillin did not. These findings suggest that combining VAN with an appropriate β-lactam, such as ceftriaxone, is therapeutically effective against infectious diseases caused by VRSA.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99–139 (2010).
Chang, S. et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348, 1342–1347 (2003).
Melo-Cristino, J., Resina, C., Manuel, V., Lito, L. & Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 382, 205 (2013).
Robert, J., Bismuth, R. & Jarlier, V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57, 506–510 (2006).
Ishino, K., Ishikawa, J., Ikeda, Y. & Hotta, K. Characterization of a bifunctional aminoglycoside-modifying enzyme with novel substrate specificity and its gene from a clinical isolate of methicillin-resistant Staphylococcus aureus with high arbekacin resistance. J. Antibiot. (Tokyo) 57, 679–686 (2004).
Wilson, P. et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51, 186–188 (2003).
Mehta, S. et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56, 92–102 (2012).
Ishii, K. et al. Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis. Sci. Rep. 5, 17092 (2015).
Werth, B. J. et al. Novel combinations of vancomycin plus ceftaroline or against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob. Agents Chemother. 57, 2376–2379 (2013).
Domenech, A. et al. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 56, 709–716 (2005).
Kaito, C., Akimitsu, N., Watanabe, H. & Sekimizu, K. Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb. Pathog. 32, 183–190 (2002).
Matsumoto, Y. et al. Quantitative evaluation of cryptococcal pathogenesis and antifungal drugs using a silkworm infection model with Cryptococcus neoformans. J. Appl. Microbiol. 112, 138–146 (2012).
Hamamoto, H. et al. Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob. Agents Chemother. 48, 774–779 (2004).
Uchida, R., Namiguchi, S., Ishijima, H. & Tomoda, H. Therapeutic effects of three trichothecenes in the silkworm infection assay with Candida albicans. Drug Discov. Ther. 10, 44–48 (2016).
Usui, K. et al. Acute oral toxicity test of chemical compounds in silkworms. Drug Discov. Ther. 10, 57–61 (2016).
Fujiyuki, T., Imamura, K., Hamamoto, H. & Sekimizu, K. Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection. Drug Discov. Ther 4, 349–354 (2010).
Hamamoto, H. et al. Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat. Chem. Biol. 11, 127–133 (2015).
Uchida, R. et al. In vitro and in vivo anti-MRSA activities of nosokomycins. Drug Discov. Ther. 8, 249–254 (2014).
Uchida, R. et al. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. I: fermentation, isolation and biological properties. J. Antibiot. (Tokyo) 63, 151–155 (2010).
Tomoda, H. New approaches to drug discovery for combating MRSA. Chem. Pharm. Bull. (Tokyo) 64, 104–111 (2016).
Uchida, R., Iwatsuki, M., Kim, Y. P., Omura, S. & Tomoda, H. Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. II: structure elucidation. J. Antibiot. (Tokyo) 63, 157–163 (2010).
Hiramatsu, K. et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350, 1670–1673 (1997).
Odawara, M., Hamada, I. & Suzuki, M. Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus. Diabetes Ther. 5, 169–181 (2014).
He, Y. L. et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin. Pharmacokinet. 46, 577–588 (2007).
Kajbaf, F., Bennis, Y., Hurtel-Lemaire, A. S., Andrejak, M. & Lalau, J. D. Unexpectedly long half-life of metformin elimination in cases of metformin accumulation. Diabet. Med 33, 105–110 (2016).
Lee, F. H., Pfeffer, M., Van Harken, D. R., Smyth, R. D. & Hottendorf, G. H. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob. Agents Chemother. 17, 188–192 (1980).
Barza, M. & Weinstein, L. Some determinants of the distribution of penicillins and cephalosporins in the body. Practical and theoretical considerations. Ann. NY Acad. Sci. 235, 613–620 (1974).
Van Bambeke, F., Van Laethem, Y., Courvalin, P. & Tulkens, P. M. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64, 913–936 (2004).
Lamb, H. M., Ormrod, D., Scott, L. J. & Figgitt, D. P. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 62, 1041–1089 (2002).
Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775–781 (2000).
Katayama, Y., Ito, T. & Hiramatsu, K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 44, 1549–1555 (2000).
Hartman, B. J. & Tomasz, A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J. Bacteriol. 158, 513–516 (1984).
Ubukata, K., Nonoguchi, R., Matsuhashi, M. & Konno, M. Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J. Bacteriol. 171, 2882–2885 (1989).
Komatsuzawa, H., Suzuki, J., Sugai, M., Miyake, Y. & Suginaka, H. Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 33, 1155–1163 (1994).
Domaracki, B. E., Evans, A. M. & Venezia, R. A. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 44, 1394–1396 (2000).
Drago, L., De Vecchi, E., Nicola, L. & Gismondo, M. R. In vitro evaluation of antibiotics’ combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect. Dis. 7, 111 (2007).
Steinkraus, G., White, R. & Friedrich, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J. Antimicrob. Chemother. 60, 788–794 (2007).
Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 (2004).
Mizushima, T. Drug discovery and development focusing on existing medicines: drug re-profiling strategy. J. Biochem. 149, 499–505 (2011).
Bushby, S. R. & Hitchings, G. H. Trimethoprim, a sulphonamide potentiator. Br. J. Pharmacol. Chemother. 33, 72–90 (1968).
Acknowledgements
This project was supported by JSPS KAKENHI grant number JP15H05783 (Scientific Research (S) to KS).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
KS has an advisory role at Genome Pharmaceuticals Institute (Tokyo, Japan). The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Tabuchi, F., Matsumoto, Y., Ishii, M. et al. Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus. J Antibiot 70, 771–774 (2017). https://doi.org/10.1038/ja.2017.7
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2017.7
This article is cited by
-
Discovery of new AMR drugs targeting modulators of antimicrobial activity using in vivo silkworm screening systems
The Journal of Antibiotics (2025)
-
In vitro antagonistic inhibitory effects of palm seed crude oils and their main constituent, lauric acid, with oxacillin in Staphylococcus aureus
Scientific Reports (2021)
-
Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?
Infectious Diseases and Therapy (2019)
-
D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus
The Journal of Antibiotics (2017)
